{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:03:57Z","timestamp":1767175437358,"version":"build-2238731810"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vascular endothelial growth factor inhibitors (VEGFIs) are used to treat malignant neoplasms and ocular diseases by inhibiting angiogenesis. Systemic use of VEGFIs has various side effects, including hypertension, proteinuria, and thrombotic microangiopathy, but adverse events due to intravitreal injection of VEGFIs have not been fully clarified. Although age-related macular degeneration was initially the most common target of intravitreal injection of VEGFIs, it has also been applied sporadically for diabetic macular edema in recent years. Proteinuria following intravitreal injection of VEGFIs would be reversible. In patients with diabetes mellitus (DM), however, it would be difficult to determine whether kidney damage arises from the clinical course of DM or from intravitreal injection of VEGFIs for diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 55-year-old woman with a 20-year history of type 2 DM began intravitreal injection of VEGFI (aflibercept, 2\u00a0mg every 4\u00a0weeks) for treatment of diabetic macular edema 2\u00a0years previously. She presented with leg edema, hypertension, and nephrotic-range proteinuria 14\u00a0months after the first injection. Histological examination of renal biopsy specimens revealed diabetic nephropathy with renal thrombotic microangiopathy probably associated with intravitreal injection of VEGFI. The patient\u2019s nephrotic syndrome completely improved at 6\u00a0months after simply discontinuing aflibercept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is a precious report of pathologically investigated renal thrombotic microangiopathy leading to nephrotic syndrome due to intravitreal injection of aflibercept for diabetic macular edema in a patient with type 2 DM. Renal function and proteinuria should be monitored in diabetic patients who receive intravitreal injection of a VEGFI. If kidney damage develops independent of the clinical course of DM during intravitreal injection of a VEGFI, renal biopsy should be performed and intravitreal VEGFI injection discontinued.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-022-02986-2","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:28:42Z","timestamp":1667089722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema"],"prefix":"10.1186","volume":"23","author":[{"given":"Yawara","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Odashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4797-8228","authenticated-orcid":false,"given":"Kazuhiro","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyasu","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Asahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"issue":"3","key":"2986_CR1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.kint.2019.02.042","volume":"96","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Barsoum M, Arman F. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572\u201380. https:\/\/doi.org\/10.1016\/j.kint.2019.02.042.","journal-title":"Kidney Int"},{"issue":"1","key":"2986_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/MNH.0000000000000760","volume":"31","author":"RM Hanna","year":"2022","unstructured":"Hanna RM, Ahdoot RS, Kim MS, Jhaveri KD, Kalantar-Zadeh K, Kurtz IB. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. Curr Opin Nephrol Hypertens. 2022;31(1):47\u201356. https:\/\/doi.org\/10.1097\/MNH.0000000000000760.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"2986_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30(2):187\u2013200. https:\/\/doi.org\/10.1681\/ASN.2018080853.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"2986_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","volume":"34","author":"WM Amoaku","year":"2020","unstructured":"Amoaku WM, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey L, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020;34(Suppl 1):1\u201351. https:\/\/doi.org\/10.1038\/s41433-020-0961-6.","journal-title":"Eye (Lond)"},{"issue":"11","key":"2986_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113701","volume":"9","author":"A Tschulakow","year":"2014","unstructured":"Tschulakow A, Christner S, Julien S, Ludinsky M, Giet M, Schraermeyer U. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE. 2014;9(11): e113701. https:\/\/doi.org\/10.1371\/journal.pone.0113701.","journal-title":"PLoS ONE"},{"issue":"3","key":"2986_CR6","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1167\/iovs.17-22853","volume":"59","author":"AR Glassman","year":"2018","unstructured":"Glassman AR, Liu D, Jampol LM, Sun JK. Diabetic Retinopathy Clinical Research Network. Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59(3):1199\u2013205. https:\/\/doi.org\/10.1167\/iovs.17-22853.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2986_CR7","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.22086\/gmj.v0i0.1299","volume":"7","author":"SD Bagheri","year":"2018","unstructured":"Bagheri SD, Afarid M, Sagheb MM. Proteinuria and renal dysfunction after intravitreal injection of bevacizumab in patients with diabetic nephropathy: a prospective observational study. Galen Med J. 2018;7:e1299. https:\/\/doi.org\/10.22086\/gmj.v0i0.1299.","journal-title":"Galen Med J"},{"issue":"4","key":"2986_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/jdi.12771","volume":"9","author":"Y Kameda","year":"2018","unstructured":"Kameda Y, Babazono T, Uchigata Y, Kitano S. Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease. J Diabetes Investig. 2018;9(4):937\u20139. https:\/\/doi.org\/10.1111\/jdi.12771.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2986_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12882-019-1650-1","volume":"20","author":"RA O\u2019Neill","year":"2019","unstructured":"O\u2019Neill RA, Gallagher P, Douglas T, Little JA, Maxwell AP, Silvestri G, et al. Evaluation of longterm intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease. BMC Nephrol. 2019;20(1):478. https:\/\/doi.org\/10.1186\/s12882-019-1650-1.","journal-title":"BMC Nephrol"},{"key":"2986_CR10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/ndt\/gfaa142.P0590","volume":"142","author":"M Jalalonmuhali","year":"2020","unstructured":"Jalalonmuhali M, Kamalden TAFT, Ismail NS, Yong SY, Teo WT, Lim SK. Adverse renal outcome following administration of intravitreal anti-vascular endothelial growth factor inhibitors in a single tertiary centre in Malaysia. Nephrol Dial Transplant. 2020;142:590. https:\/\/doi.org\/10.1093\/ndt\/gfaa142.P0590.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2986_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.9.4.4","volume":"9","author":"YR Chung","year":"2020","unstructured":"Chung YR, Kim YH, Byeon HE, Jo DH, Kim JH, Lee K. Effect of a single intravitreal injection of bevacizumab on proteinuria in patients with diabetes. Transl Vis Sci Technol. 2020;9(4):4. https:\/\/doi.org\/10.1167\/tvst.9.4.4.","journal-title":"Transl Vis Sci Technol"},{"issue":"8","key":"2986_CR12","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/eye.2008.360","volume":"23","author":"R Rasier","year":"2009","unstructured":"Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond). 2009;23(8):1714\u20138. https:\/\/doi.org\/10.1038\/eye.2008.360.","journal-title":"Eye (Lond)"},{"issue":"10","key":"2986_CR13","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/IAE.0b013e3181b21056","volume":"29","author":"K Lee","year":"2009","unstructured":"Lee K, Yang H, Lim H, Lew HM. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina. 2009;29(10):1409\u201317. https:\/\/doi.org\/10.1097\/IAE.0b013e3181b21056.","journal-title":"Retina"},{"issue":"6","key":"2986_CR14","first-page":"435","volume":"54","author":"D Risimic","year":"2013","unstructured":"Risimic D, Milenkovic S, Nikolic D, Simeunovic D, Jaksic V, Stojkovic M, et al. Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration. Hellenic J Cardiol. 2013;54(6):435\u201340.","journal-title":"Hellenic J Cardiol"},{"issue":"5","key":"2986_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.oret.2019.01.019","volume":"3","author":"AR Shah","year":"2019","unstructured":"Shah AR, Van Horn AN, Verchinina L, Wichorek M, Su L, Markel D, et al. Blood pressure is associated with receiving intravitreal anti-vascular endothelial growth factor treatment in patients with diabetes. Opththalmol Retina. 2019;3(5):410\u20136. https:\/\/doi.org\/10.1016\/j.oret.2019.01.019.","journal-title":"Opththalmol Retina"},{"issue":"1","key":"2986_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","volume":"134","author":"RL Avery","year":"2016","unstructured":"Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and metaanalysis. JAMA Ophthalmol. 2016;134(1):21\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.4070.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2986_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12886-017-0586-0","volume":"17","author":"J Hanhart","year":"2017","unstructured":"Hanhart J, Comaneshter DS, Freier Dror Y, Vinker S. Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration. BMC Ophthalmol. 2017;17(1):189. https:\/\/doi.org\/10.1186\/s12886-017-0586-0.","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"2986_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00417-018-3917-9","volume":"256","author":"J Hanhart","year":"2018","unstructured":"Hanhart J, Comaneshter DS, Freier-Dror Y, Vinker S. Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):651\u201363. https:\/\/doi.org\/10.1007\/s00417-018-3917-9.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2986_CR19","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1111\/aos.13731","volume":"96","author":"J Hanhart","year":"2018","unstructured":"Hanhart J, Comaneshter DS, Vinker S. Mortality after a cerebrovascular event in age-related macular degeneration patients treated with bevacizumab ocular injections. Acta Ophthalmol. 2018;96(6):e732\u20139. https:\/\/doi.org\/10.1111\/aos.13731.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"2986_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","volume":"137","author":"LA Dalvin","year":"2019","unstructured":"Dalvin LA, Starr MR, AbouChehade JE, Damento GM, Garcia M, Shah SM, et al. Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol. 2019;137(5):483\u201390. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.6891.","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"2986_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1053\/j.ajkd.2010.11.030","volume":"57","author":"G Pell\u00e9","year":"2011","unstructured":"Pell\u00e9 G, Shweke N, Van Huyen J-PD, Tricot L, Hessa\u00efne S, Fr\u00e9meaux-Bacchi V, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57(5):756\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2010.11.030.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2986_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcjo.2011.12.024","volume":"47","author":"HR Anto","year":"2012","unstructured":"Anto HR, Hyman GF, Li JP, Spitalewitz S, Thomas D. Membranous nephropathy following intravitreal injection of bevacizumab. Can J Ophthalmol. 2012;47(1):84\u20136. https:\/\/doi.org\/10.1016\/j.jcjo.2011.12.024.","journal-title":"Can J Ophthalmol"},{"issue":"11","key":"2986_CR23","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1097\/TP.0000000000000750","volume":"99","author":"W Cheungpasitporn","year":"2015","unstructured":"Cheungpasitporn W, Chebib FT, Cornell LD, Brodin ML, Nasr SH, Schinstock CA, et al. Intravitreal anti-vascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts. Transplant. 2015;99(11):2382\u20136. https:\/\/doi.org\/10.1097\/TP.0000000000000750.","journal-title":"Transplant"},{"issue":"3","key":"2986_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.15171\/jnp.2017.23","volume":"6","author":"G Khneizer","year":"2017","unstructured":"Khneizer G, Al-Taee A, Bastani B. Self-limited membranous nephropathy after Intravitreal nephropathy after intravitreal bevacizumab therapy for age related macular degeneration. J Nephropathol. 2017;6(3):134\u20137. https:\/\/doi.org\/10.15171\/jnp.2017.23.","journal-title":"J Nephropathol"},{"issue":"4","key":"2986_CR25","doi-asserted-by":"publisher","first-page":"A99","DOI":"10.1053\/j.ajkd.2017.02.339","volume":"69","author":"D Valsan","year":"2017","unstructured":"Valsan D, Kazi S. Intravitreal VEGF inhibitor causing allergic interstitial nephritis. Am J Kidney Dis. 2017;69(4):A99. https:\/\/doi.org\/10.1053\/j.ajkd.2017.02.339.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2986_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/ckj\/sfy060","volume":"12","author":"RM Hanna","year":"2019","unstructured":"Hanna RM, Lopez E, Hasnain H, Selamet U, Wilson J, Youssef PN, et al. Three patients with injection of intravitreal vascular endothelial growth facto inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2019;12(1):92\u2013100. https:\/\/doi.org\/10.1093\/ckj\/sfy060.","journal-title":"Clin Kidney J"},{"issue":"10","key":"2986_CR27","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.ekir.2019.07.019","volume":"4","author":"NN Nobakht","year":"2019","unstructured":"Nobakht NN, Nguyen HA, Kamgar MK, Abdelnour L, Rastogi A, Hanna RM. Development of collapsing focal and segmental glomerulosclerosis in a patient receiving intravitreal vascular endothelial growth factor blockade. Kidney Int Rep. 2019;4(10):1508\u201312. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.019.","journal-title":"Kidney Int Rep"},{"key":"2986_CR28","doi-asserted-by":"publisher","first-page":"2919080","DOI":"10.1155\/2019\/2919080","volume":"2019","author":"F Touzani","year":"2019","unstructured":"Touzani F, Geers C, Pozdzik A. Intravitreal injection of antiVEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019;2019:2919080. https:\/\/doi.org\/10.1155\/2019\/2919080.","journal-title":"Case Rep Nephrol"},{"key":"2986_CR29","unstructured":"Yin W, Zhang PL. Intravitreal injection of avastin (IIA) over time can be associated with thromobtic microangiopathy (TMA) in the native kidney. J Am Soc Nephrol. 2019;30:153-4."},{"issue":"6","key":"2986_CR30","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/ckj\/sfaa049","volume":"13","author":"M Shye","year":"2020","unstructured":"Shye M, Hanna RM, Patel SS, Tram-Tran N, Hou J, Mccannel C, et al. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J. 2020;13(6):969\u201380. https:\/\/doi.org\/10.1093\/ckj\/sfaa049.","journal-title":"Clin Kidney J"},{"issue":"23","key":"2986_CR31","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.2169\/internalmedicine.5410-20","volume":"59","author":"K Kakeshita","year":"2020","unstructured":"Kakeshita K, Koike T, Imamura T, Murai S, Fujioka H, Yamazaki H, et al. Nephrotic syndrome with focal segmental glomerulosclerosis induced by intravitreal injections of vascular endothelial growth factor inhibitor. Intern Med. 2020;59(23):5410\u201320. https:\/\/doi.org\/10.2169\/internalmedicine.5410-20.","journal-title":"Intern Med"},{"key":"2986_CR32","doi-asserted-by":"publisher","first-page":"579603","DOI":"10.3389\/fmed.2020.579603","volume":"7","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Tran NT, Patel SS, Hou J, Jhaveri KD, Parikh R, et al. Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use. Front Med (Lausanne). 2020;7:579603. https:\/\/doi.org\/10.3389\/fmed.2020.579603.","journal-title":"Front. Med (Lausanne)"},{"key":"2986_CR33","doi-asserted-by":"publisher","first-page":"2050313X2095265","DOI":"10.1177\/2050313X20952650","volume":"8","author":"RM Hanna","year":"2020","unstructured":"Hanna RM, Abdelnour L, Zuckerman JE, Ferrey AJ, Pai A, Vahabzadeh K, et al. Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab. SAGE Open Med Case Rep. 2020;8:2050313X20952650. https:\/\/doi.org\/10.1177\/2050313X20952650.","journal-title":"SAGE Open Med Case Rep"},{"issue":"10","key":"2986_CR34","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1093\/ckj\/sfab066","volume":"14","author":"G Phadke","year":"2021","unstructured":"Phadke G, Hanna RM, Ferrey AJ, Torres EA, Singla A, Kaushal A, et al. Review of intravitreal vascular endothelial growth factor inhibitor toxcitiy, and report of collpasing focal and segmental sclerosis with thrombotic microangiopathy in a patient with age-related macular degeneration. Clin Kidney J. 2021;14(10):2158\u201365. https:\/\/doi.org\/10.1093\/ckj\/sfab066.","journal-title":"Clin Kidney J"},{"issue":"12","key":"2986_CR35","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636\u201341. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305252.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"2986_CR36","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847\u201358. https:\/\/doi.org\/10.1097\/IAE.0000000000001493.","journal-title":"Retina"},{"key":"2986_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40942-020-00234-z","volume":"6","author":"MA Sadiq","year":"2020","unstructured":"Sadiq MA, Halim MS, Hassan M, Onghanseng N, Karaca I, Agarwal A, et al. Pharmacological agents in development for diabetic macular edema. Int J Retina Vitreous. 2020;6:29. https:\/\/doi.org\/10.1186\/s40942-020-00234-z.","journal-title":"Int J Retina Vitreous"},{"key":"2986_CR38","first-page":"739","volume-title":"Heptinstall\u2019s Pathology of the Kidney","author":"ZG Laszik","year":"2015","unstructured":"Laszik ZG, Kambham N, Silva FG. Thrombotic Microangiopathies. In: Jannette JC, Olson JL, Silva FG, D\u2019Agati VD, editors. Heptinstall\u2019s Pathology of the Kidney, vol. II. 7th ed. Philadelphia, PA, USA: Wolters Kluwer; 2015. p. 739\u2013814.","edition":"7"},{"issue":"5","key":"2986_CR39","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40620-020-00797-y","volume":"33","author":"AD Vincenzo","year":"2020","unstructured":"Vincenzo AD, Battini S, Russo L, Mazzocut S, Mauer M, Fioretto P. Renal structure in type 2 diabetes: facts and misconceptions. J Nephrol. 2020;33(5):901\u20137. https:\/\/doi.org\/10.1007\/s40620-020-00797-y.","journal-title":"J Nephrol"},{"issue":"5","key":"2986_CR40","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","volume":"32","author":"F Person","year":"2019","unstructured":"Person F, Rinschen MM, Brix SR, Wulf S, Noriega MM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32(5):684\u2013700. https:\/\/doi.org\/10.1038\/s41379-018-0186-4.","journal-title":"Mod Pathol"}],"updated-by":[{"DOI":"10.1186\/s12882-022-03006-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000}}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02986-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02986-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T22:09:19Z","timestamp":1671833359000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02986-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2986"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02986-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"23 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12882-022-03006-z","URL":"https:\/\/doi.org\/10.1186\/s12882-022-03006-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}